Market Context — Why This Technology, Why Now

Global regulatory bodies are tightening standards for contaminant detection in food and water, while healthcare systems demand earlier, less invasive disease diagnostics. This creates immense pressure on industries to adopt next-generation analytical tools. The competitive landscape in diagnostics and quality control favors solutions offering superior sensitivity and faster turnaround, enabling companies to reduce retesting costs and accelerate R&D. This technology provides a critical advantage in meeting these evolving market and regulatory demands.

Key Competitive Advantages
01

Achieves over 100x greater detection sensitivity compared to conventional methods.

02

Streamlines analysis by significantly reducing complex pre-processing steps and shortening analysis time.

03

Ensures stable, high-precision detection through protected nanotags and efficient release.

Market Opportunity
Medical Diagnostics (Early Disease Detection)
$10B–$15B globally (AI est.)
Advancements in personalized medicine and the increasing importance of early disease detection are driving a surge in demand for highly sensitive detection of trace biomarkers.
Major diagnostic kit manufacturers Clinical pathology laboratories Personalized medicine developers
Food Safety Testing
$8B–$12B globally (AI est.)
Growing consumer awareness of food safety and security demands rapid, high-precision detection of allergens, pathogens, and pesticide residues from food manufacturers and testing agencies.
Food processing equipment manufacturers Food quality control labs Agricultural technology providers
Environmental Monitoring
$8B–$12B globally (AI est.)
Demand is expanding for real-time, high-sensitivity detection of trace harmful substances in the environment, such as water, air, and soil pollutants, driven by stricter environmental regulations.
Environmental sensor manufacturers Water treatment solution providers Government environmental agencies
IP Defensibility — Why Competitors Can't Replicate This
What This Patent Covers

This patent protects a nanogel, a kit, and a detection method across 14 claims, covering a broad technical scope. It successfully overcame a rejection during examination, demonstrating clear superiority over nine cited prior art documents and establishing a robust, stable right. This provides a strong foundation for commercialization.

Competitive White Space

While strong in SERS-based detection, the patent leaves white space for integrating this nanogel technology with other spectroscopic methods or for developing novel in-vivo biosensing applications. Further IP could also be built around specific analytical device integrations or advanced data processing algorithms.

Economic Impact
~$150K/year estimated cost reduction per facility (est.)
estimated ROI · USD · AI analysis
ROI Calculation Logic

For a medical diagnostic lab processing 10,000 samples annually, conventional methods (e.g., ELISA) are estimated to cost ~$35/sample (AI est.), leading to an annual operational cost of ~$350K (AI est.). Implementing this technology could reduce retesting rates by 20% due to higher sensitivity and cut reagent/labor costs by 30% through simplified pre-processing. This would reduce annual costs to ~$350K × (1 - 0.2) × (1 - 0.3) = ~$200K (AI est.), resulting in an estimated annual savings of ~$150K (AI est.).

Speed to Market
5× faster than in-house development
This technology is a research outcome from Shizuoka University, with the foundational technology assumed to be established. The synthesis of stimulus-responsive nanogels and the capture/release mechanisms of SERS nanotags are likely verified, providing a clear roadmap from proof-of-concept to commercialization. The rights holder's proactive stance on licensing is expected to significantly shorten development periods post-introduction, enabling rapid market entry. This represents an estimated ~3.2-year reduction compared to in-house development.
Competitive Positioning

X: Detection Sensitivity & Specificity
Y: Analysis Speed & Automation Efficiency

Business Models & Applications
🤝 Licensing Model
A model for generating royalty income by licensing the patent rights of this technology to companies developing high-sensitivity biodetection devices and kits.
🔬 Collaborative Development & OEM Model
A model that deeply integrates technology with market needs by engaging in joint development for specific applications (e.g., diagnostics for particular diseases) and supplying the results as OEM products.
🧪 Analytical Service Provider Model
A model for generating service fees by building a high-sensitivity analytical platform using this technology and offering analytical services to pharmaceutical companies, food manufacturers, and research institutions.
Adjacent Application Opportunities
💊 Drug Discovery & R&D
High-Throughput Screening
This technology's high-sensitivity detection could be applied to screen trace drug candidates and biomolecular interactions rapidly and precisely in drug discovery research. This has the potential to significantly reduce new drug development time and costs by an estimated 20-30%.
🐄 Livestock & Agriculture
Rapid Pathogen Diagnosis for Livestock & Crops
This technology could be repurposed as a device for rapid, high-sensitivity detection of livestock infections and crop pathogens in the field. This would contribute to early disease detection and prevention of spread, potentially reducing crop losses by 15-25%.
👮‍♂️ Security & Defense
Explosives & Narcotics Trace Detection
This technology could be applied as a system for high-sensitivity detection of trace explosives and illicit drugs in security checks at airports and critical facilities. This could enhance national security by improving detection rates by over 50%.
Integration Roadmap — Estimated 22-Month Deployment
Phase 1: Technology Evaluation & Prototype Validation
Duration: 4 months
Detailed evaluation of the technology's foundational data and proof-of-concept for a prototype tailored to the licensee's specific application. Confirm reproducibility of nanogel synthesis and SERS measurements.
Phase 2: Product Development & Field Testing
Duration: 9 months
Develop a practical detection device or kit based on the prototype. Conduct field tests in the target environment to verify performance and reliability.
Phase 3: Mass Production Preparation & Market Launch
Duration: 9 months
Establish mass production systems for the developed product, prepare for regulatory submissions, and formulate/execute a strategic market entry plan. Strengthen collaboration with initial adoption partners.
Technical Feasibility
This technology is based on a modular structure of stimulus-responsive nanogels containing SERS nanotags, making integration into existing Raman spectroscopy instruments and general bio-analytical platforms relatively straightforward. By binding specific target probes to the nanogel surface, it can be applied to diverse detection systems. Early implementation is expected by integrating it into existing analytical workflows without requiring significant new capital investment.
Success Scenario
Upon adopting this technology, the medical diagnostics sector could achieve ultra-early detection of diseases through the highly sensitive identification of trace biomarkers. This may reduce patient burden and expand treatment options, potentially improving diagnostic accuracy and speed for thousands of cases annually, while also contributing to healthcare cost reduction. In food safety, faster quality control could shorten product shipment lead times by an estimated 20%.
Patent Record
APPLICATION NO.
特願2021-001391
REGISTRATION NO.
7591260
FILING DATE
2021/01/07
GRANT DATE
2024/11/20
EXPIRATION DATE
2041/01/07
PATENT HOLDER
国立大学法人静岡大学
Examination History
2023年11月28日
出願審査請求書
2024年10月08日
拒絶理由通知書
2024年10月21日
手続補正書（自発・内容）
2024年10月21日
意見書
2024年11月05日
特許査定